Compare OPAL & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OPAL | SCLX |
|---|---|---|
| Founded | 1998 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 77.0M | 90.0M |
| IPO Year | N/A | N/A |
| Metric | OPAL | SCLX |
|---|---|---|
| Price | $2.36 | $9.47 |
| Analyst Decision | Sell | Hold |
| Analyst Count | 4 | 1 |
| Target Price | ★ $2.81 | N/A |
| AVG Volume (30 Days) | ★ 332.3K | 80.0K |
| Earning Date | 03-12-2026 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $329,243,000.00 | $40,360,000.00 |
| Revenue This Year | $17.13 | N/A |
| Revenue Next Year | $21.75 | $749.70 |
| P/E Ratio | $106.09 | ★ N/A |
| Revenue Growth | ★ 7.26 | N/A |
| 52 Week Low | $1.26 | $3.60 |
| 52 Week High | $4.08 | $34.27 |
| Indicator | OPAL | SCLX |
|---|---|---|
| Relative Strength Index (RSI) | 45.68 | 27.34 |
| Support Level | $2.35 | $10.35 |
| Resistance Level | $2.78 | $12.30 |
| Average True Range (ATR) | 0.17 | 1.05 |
| MACD | -0.01 | -0.12 |
| Stochastic Oscillator | 38.35 | 1.94 |
OPAL Fuels Inc is a fully integrated, nationwide leader in the production and distribution of low-carbon intensity renewable natural gas. The company is also engaged in the marketing and distribution of RNG to heavy-duty trucking and other hard-to-de-carbonize industrial sectors. The company designs, develops, constructs, operates, and services Fueling Stations for trucking fleets across the country that use natural gas to displace diesel as their transportation fuel. The company derives revenue from the sale of Renewable Power, design, development, construction, and service of Fueling Stations, and sales of RNG produced by OPAL and third parties as pipeline-quality natural gas.
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.